SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

2/11/22 1:24:42 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LGND alert in real time by email

SC 13G/A 1 lgnd222.txt SCHEDULE 13G Amendment No. 1 Name of Issuer: Ligand Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 53220K504 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 195,197 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 195,197 Item 8: Shared Dispositive Power: 0 Item 9: Aggregate Amount Owned: 195,197 Item 10: Check Box If Aggregate Amount Excludes Certain Shares: N/A Item 11: Percent of Class Owned: 1.2% Item 12: Type of Reporting Person: IA Item 1(a): Name of Issuer: Ligand Pharmaceuticals Inc. Item l(b): Address of Issuer: 3911 Sorrento Valley Blvd, Ste 110, San Diego, CA 92121 Item 2(a): Name of Person Filing: Wasatch Advisors, Inc. Item 2(b): Address: 505 Wakara Way, Salt Lake City, UT 84108 Item 2(c): Citizenship: Not Applicable Item 2(d): Title of Class of Securities: Common Stock Item 2(e): CUSIP Number: 53220K504 Item 3(e): Investment Adviser registered under section 203 of the Investment Advisers Act of 1940 Item 4(a): Amount Owned: 195,197 Item 4(b): Percent of Class Owned: 1.2% Item 4(c)(i): Sole Voting Power: 195,197 Item 4(c)(ii): Shared Voting Power: 0 Item 4(c)(iii): Sole Dispositive Power: 195,197 Item 4(c)(iv): Shared Dispositive Power: 0 Item 5: Check Box If Ownership Is 5% or Less of Class: [X] Item 6. Ownership of More Than 5% on Behalf of Another Person: N/A Item 7: Identification of Subsidiary: Not Applicable Item 8: Identification of Members of Group: Not Applicable Item 9: Notice of Dissolution of Group: Not Applicable Item 10: Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of December 31, 2021. Date: 02/11/22 Signature: /s/JB Taylor Name/Title: JB Taylor/CEO

Get the next $LGND alert in real time by email

Date	Price Target	Rating	Analyst
4/10/2025	$143.00	Buy	Stifel
10/3/2024	$135.00	Outperform	Oppenheimer
7/30/2024	$130.00	Outperform	RBC Capital Mkts
2/22/2022	$180.00 → $130.00	Buy	Benchmark
2/18/2022	$185.00 → $165.00	Overweight	Barclays
9/22/2021	$174.00 → $180.00	Overweight	Barclays
7/30/2021	$200.00 → $190.00	Buy	Roth Capital

SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

Chat with this insight

Recent Analyst Ratings for
$LGND

SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

Chat with this insight

Recent Analyst Ratings for $LGND

Recent Analyst Ratings for
$LGND